Company: CRNX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-029050
Chunk: 5

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 5
---
 )

    Increase (decrease) in cash resulting from changes in:

    Prepaid expenses and other assets

    (5,974
    )

    (4,523
    )

    215

    Accounts payable and accrued expenses, compensation and related expenses, and other non-current liabilities

    17,541

    14,648

    10,994

    Deferred revenue

    74

    (1,535
    )

    8,341

    Operating lease liabilities

    (6
    )

    (546
    )

    (938
    )

    Net cash used in operating activities

    (225,970
    )

    (166,307
    )

    (115,205
    )

    Investing activities:

    Purchases of investment securities

    (1,146,772
    )

    (527,857
    )

    (329,817
    )

    Purchase of Radionetics preferred stock

    —

    (5,000
    )

    —

    Maturities of investment securities

    575,799

    337,132

    157,493

    Purchases of property and equipment

    (3,844
    )

    (4,688
    )

    (1,656
    )

    Net cash used in investing activities

    (574,817
    )

    (200,413
    )

    (173,980
    )

    Financing activities:

    Proceeds from issuance of common stock, net of $49,442 (2024), $22,735 (2023) and $7,758 (2022) transaction costs

    970,048

    369,019

    117,242

    Proceeds from exercise of stock options

    40,387

    19,925

    4,721

    Net cash provided by financing activities

    1,010,435

    388,944

    121,963

    Net change in cash, cash equivalents and restricted cash

    209,648

    22,224

    (167,222
    )

    Cash, cash equivalents and restricted cash - beginning of period

    56,197

    33,973

    201,195

    Cash, cash equivalents and restricted cash - end of period
     
    $
    265,845

    $